Coexisting Heart Failure and Chronic Obstructive Pulmonary Disease: Report of Two Cases Treated with Indacaterol/Glycopyrronium
Sign Up to like & getrecommendations! Published in 2018 at "Respiration"
DOI: 10.1159/000487169
Abstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and it is associated with a high economic burden. Heart failure shares some general symptoms with COPD; thus, diagnosing COPD is… read more here.
Keywords: chronic obstructive; indacaterol glycopyrronium; heart; heart failure ... See more keywords
Long‐Term Triple Therapy De‐escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double‐Blind, Triple‐Dummy Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.201803-0405oc
Abstract: &NA; Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long‐term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the efficacy and safety of direct de‐escalation from long‐term… read more here.
Keywords: indacaterol glycopyrronium; long term; triple therapy; therapy ... See more keywords
Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Respiratory Disease"
DOI: 10.1177/1753466620939507
Abstract: Background: Exertional dyspnea is a cardinal feature of chronic obstructive pulmonary disease (COPD) and a major cause of activity limitation. Although dual bronchodilation is more effective than bronchodilator monotherapy at improving resting pulmonary function, it… read more here.
Keywords: indacaterol glycopyrronium; trial; dyspnea; tiotropium ... See more keywords
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
Sign Up to like & getrecommendations! Published in 2017 at "Respiratory Research"
DOI: 10.1186/s12931-017-0688-5
Abstract: BackgroundThis study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year.MethodsA previously published and… read more here.
Keywords: indacaterol glycopyrronium; salmeterol fluticasone; copd; cost effective ... See more keywords
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
Sign Up to like & getrecommendations! Published in 2018 at "Respiratory Research"
DOI: 10.1186/s12931-018-0830-z
Abstract: BackgroundChronic obstructive pulmonary disease (COPD) is a progressive disease and a composite endpoint could be an indicator of treatment effect on disease worsening. This post-hoc analysis assessed whether indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily reduced the… read more here.
Keywords: indacaterol glycopyrronium; copd; versus; cid patients ... See more keywords